{
  "ticker": "LLY",
  "target_date": "2025-08-28",
  "actual_date": "2025-08-28",
  "collected_at": "2025-12-08T12:12:16.499524",
  "price": {
    "open": 734.72,
    "high": 737.51,
    "low": 725.27,
    "close": 730.8866577148438,
    "volume": 3117000,
    "change_1d_pct": -0.3,
    "change_7d_pct": 4.09,
    "change_30d_pct": -3.67
  },
  "technicals": {
    "rsi_14": 84.76,
    "sma_20": 701.04,
    "sma_50": 747.04,
    "macd": -6.702,
    "macd_signal": -15.026,
    "macd_histogram": 8.324,
    "bb_upper": 789.92,
    "bb_lower": 612.17,
    "price_vs_sma20_pct": 4.26,
    "price_vs_sma50_pct": -2.16,
    "volume_ratio": 0.45
  },
  "fundamentals": {
    "market_cap": 892655828992,
    "pe_ratio": 48.78785,
    "forward_pe": 43.943512,
    "price_to_book": 37.490967,
    "price_to_sales": 15.022868,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.45,
    "pct_from_52w_low": 59.63
  },
  "macro": {
    "spy": {
      "price": 647.13,
      "change_1d_pct": 0.35,
      "change_7d_pct": 1.69
    },
    "vix": {
      "level": 14.43,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.21
    },
    "dollar_index": {
      "level": 97.81
    },
    "gold": {
      "price": 3431.8
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble",
      "source": "Yahoo",
      "datetime": 1756418340,
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.",
      "url": "https://finnhub.io/api/news?id=9622374136570124133b7c3eea222ee372c1ad715838bd4eedfe28ebd7b958ce"
    },
    {
      "headline": "Healthcare Stocks Are \u2018Priced at Panic Levels.\u2019 It\u2019s Time to Buy.",
      "source": "Yahoo",
      "datetime": 1756406460,
      "summary": "They\u2019re bargains right now, according to two key measures. Expert Jim Paulsen won\u2019t venture a guess when the prices will recover.",
      "url": "https://finnhub.io/api/news?id=fd4eb00bd44731e8992d76e1c0275a4fb0d913031c03485e261f075be376c8b7"
    },
    {
      "headline": "Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC",
      "source": "SeekingAlpha",
      "datetime": 1756402506,
      "summary": "Equillium, Inc. raises $50M to advance EQ504, a novel AhR modulator for ulcerative colitis. Phase 1 trials begin mid-2026. Click for more on EQ stock prospects.",
      "url": "https://finnhub.io/api/news?id=05298a6821a423e89829c846031602b35461c0b7ef1f4908cbbbf3f55e837930"
    },
    {
      "headline": "Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial",
      "source": "Yahoo",
      "datetime": 1756402485,
      "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE trial, demonstrating Verzenio's effectiveness in treating early breast cancer, which has reinforced confidence in the company's oncology portfolio. Meanwhile, the Phase 3 ATTAIN-2 trial for orforglipron showed promising results for",
      "url": "https://finnhub.io/api/news?id=d9463cf969c4d43b4528ebf64862637708fb4d93fa1291049b745959d78c5e44"
    },
    {
      "headline": "Eli Lilly\u2019s Verzenio boosts OS in breast cancer as Novartis rivalry heats up",
      "source": "Yahoo",
      "datetime": 1756393849,
      "summary": "The positive Phase III topline results could give Lilly an advantage against rival CDK4/6 inhibitor, Kisqali.",
      "url": "https://finnhub.io/api/news?id=df65a7a123ce62d2479d6b21923a7ff7c5a4d841387c794d6e23a9db2b30c4fb"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412129.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000236/xslF345X05/wk-form4_1756412129.xml"
    },
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412046.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000234/xslF345X05/wk-form4_1756412046.xml"
    },
    {
      "form": "8-K",
      "date": "2025-08-20",
      "description": "d929636d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634987.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000232/xslF345X05/wk-form4_1755634987.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634943.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000230/xslF345X05/wk-form4_1755634943.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}